Address : 3rd floor, B Building, 33, Gwacheon-daero 7-gil, Gwacheon-si, Gyeonggi-do, Republic of Korea
General : email@example.comIR : firstname.lastname@example.orgMedia : email@example.com
Read latest news from Bertis
BERTIS Joins 2023 Pink Festival of Pink Ribbon Campaign
- In celebration of the Breast Cancer Awareness month in October, Bertis serves as a sponsor of the event to raise awareness of early detection and regular check-up of the disease.
[Image] 2023 Pink Festival logo, Bertis logo
Bertis, a company specializing in the development of proteomics-based precision medicine technology company (led by CEOs Dong-young Noh and Seung-man Han), announced on October 13th that it will participate in the 2023 Pink Festival at the Officers’ Quarters 5 in Yongsan on October 15th, to promote awareness of early detection and regular checkup of breast cancer.
Marking its 23rd year, the Pink Festival is hosted by the Korea Breast Cancer Foundation, Korean Cancer Society, Korean Breast Cancer Society as part of the Pink Ribbon Campaign to raise awareness about a healthy lifestyle for breast health and breast cancer prevention. This year’s event will offer five fitness programs helpful for women’s health and breast health, such as Dance Fit, Piloxing, Pound Fit, Latin Fit and a 3km group run, approximately 1,000 people selected through pre-registration will participate.
In celebration of Breast Cancer Awareness Month in October, Bertis will sponsor the 2023 Pink Festival and operate a promotional booth at the event. Along with hosting a quiz to help the participants understand the importance of regular breast checkups for early breast cancer detection, Bertis will provide essential information for regular breast cancer screenings, including an introduction of MASTOCHECK®, a blood test solution for early breast cancer diagnosis.
MASTOCHECK® is the world’s first proteomics-based blood test solution for early breast cancer detection developed by Bertis. With its effectiveness in diagnosing stage 0-2 breast cancer has been verified in Korea, leading to its approval as an in vitro diagnostic medical device by the Ministry of Food and Drug Safety in 2019. As of October 2023, it is utilized by as many as 392 hospitals and health examination centers in Korea.
Bertis CEO Seungman Han said, “As a company that offers a solution for early breast cancer detection and takes a leading role in promoting breast health awareness, our participation in this event is of great significance. While we concentrate on developing technologies essential for precision medicine, targeting major diseases, including breast cancer, we are committed to enhancing public awareness that the early detection and regular checkups.”